Biomarkers for antitumor activity of bevacizumab in gastric cancer modelsYoriko Yamashita‐Kashima, Kazushige MoriBMC CancerJanuary 25, 201210.1186/1471-2407-12-37Cited by 32SaveCiteExport RISWatch citationsRelated PapersEnhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model|Oncology Reports|2013|46Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model|Oncology Letters|2017|25